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In the article, “Potential Regulatory and Commercial Environment for Biosimilars in Latin America,” by Valderilio Feijó Azevedo, Erik
Sandorff, Brian Siemak, Ronald J. Halbert, which appeared in Value in Health Regional Issues, Volume 1, Issue 2 (December 2012), the
following items are to be addressed and clariﬁed:1) On page 231, Table 3, the correct table should be:ibutes potentially affecting the development of biosimilar policies in ﬁve Latin American
Brazil Argentina Chile Mexico Venezuela
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were ﬁnalized in 2009.2) Also on page 231, the Potential Issues section should read:
Potential issues
Although there was no regulatory pathway until recently, biosimilars have been available in Mexico for many years. Because of the
increasing number of biosimilars coming into the market, the new biosimilar pathway was designed to increase access to
biosimilars while maintaining quality, efﬁcacy, and safety. As the regulatory pathway is still ﬂuid, there are a few potential issues
that could affect future regulation and subsequent utilization. Thus far only relatively simple biosimilars have been approved for
use in Mexico. As the regulatory pathway will most likely depend on the complexity of the biosimilar, more complex biosimilars
may be subject to the same clinical trial requirements as the originator biologic, as described in other biosimilar regulatory
guidance [5].3) On page 232, the Potential Issues section should read:
Chile has local production capacity for biologics. As the current regulatory guidelines for biosimilars are in development, the future
regulatory landscape remains open. Chile’s eventual biosimilar pathway, however, will most likely follow European Medicines
Agency or WHO guidelines. Our ﬁndings indicate that there may be standardized guidelines for all biosimilars with speciﬁc
requirements depending on the complexity of the molecule. Safety issues could also inﬂuence the future regulatory environment.
Although potential safety issues might slow down the progress toward developing biosimilar regulatory guidelines, our primary
research indicates that the Chilean government seems determined to press forward with a distinct regulatory pathway for
biosimilars.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 3 2 9 – 3 3 03304) On page 233, the second and third paragraph in the Discussion section should read:
Of these two pathways, the comparability pathway is fairly conventional in its similarity to the requirements brought forward by
the WHO Similar Biotherapeutic Products guidelines. The individual development pathway, however, includes reduced require-
ments, opening the door to lower complexity biosimilar products. Such a pathway deviates from the vision for biosimilars deﬁned
by the WHO and is reﬂective of a hypothesis that has emerged from this research that a conceptual bias may exist within Brazil
regarding the appropriate threshold for regulatory requirements for follow-on biologic products.
Safety problems highlight the need for distinct pathways to regulate review, approval, and pharmacovigilance processes for
biosimilars, and argue for greater transparency of government actions to incentivize the domestic production of biologics. Observed
safety issues, however, have apparently not had a major impact on governmental actions to increase access to biosimilars in the
region to date.
